Literature DB >> 2394012

Activation and decreased deformability of neutrophils after intermittent claudication.

F J Neumann1, W Waas, C Diehm, T Weiss, H M Haupt, R Zimmermann, H Tillmanns, W Kübler.   

Abstract

This study investigated local alterations in neutrophil activation and deformability after intermittent claudication. In 17 patients with one-sided peripheral arterial occlusive disease, neutrophil count, proportion of activated neutrophils (by nitro blue tetrazolium test), and neutrophil filterability as a measure of passive deformability were assessed in the femoral arterial and venous blood of the diseased leg and in the femoral venous blood of the healthy leg (n = 10). The values were obtained at rest, immediately after claudication, and 10 minutes after claudication induced by repetitive toe stands. Immediately after exercise, the arterial and venous blood differences in the diseased leg were 1) neutrophil count, 9% (95% confidence interval [CI], 5-14%; relative increase in the venous blood compared with arterial blood); 2) the proportion of activated neutrophils, 26% (CI, 10-42%); and 3) the neutrophil filterability, -10% (CI, -4% to -15%). At rest and 10 minutes after exercise, neutrophil parameters did not differ significantly between the femoral arterial and venous blood. Furthermore, no arterial and venous blood differences in the neutrophil parameters were found in the healthy leg. In addition to local changes, systemic changes occurred immediately after exercise. In the femoral arterial blood, the total neutrophil count had risen by 13% (CI, 8-18%), the proportion of activated neutrophils had risen by 41% (CI, 25-58%), and average neutrophil rigidity had risen 17% (CI, 11-22%) compared with the values obtained before exercise. At 10 minutes after exercise, all neutrophil parameters were still elevated. We conclude that even short periods of ischemia, as in intermittent claudication, cause local alterations in neutrophil function and distribution.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2394012     DOI: 10.1161/01.cir.82.3.922

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Effect of gallopamil on myocardial ischaemia during percutaneous transluminal coronary angioplasty.

Authors:  B Rauch; J Neumann; G Richardt; R Kranzhöfer; R Barth; R Zimmermann; H P Koch; H Tillmanns; A Schömig
Journal:  Drugs       Date:  1991       Impact factor: 9.546

2.  Peripheral artery disease affects the function of the legs of claudicating patients in a diffuse manner irrespective of the segment of the arterial tree primarily involved.

Authors:  Todd J Leutzinger; Panagiotis Koutakis; Matthew A Fuglestad; Hafizur Rahman; Holly Despiegelaere; Mahdi Hassan; Molly Schieber; Jason M Johanning; Nick Stergiou; G Matthew Longo; George P Casale; Sara A Myers; Iraklis I Pipinos
Journal:  PLoS One       Date:  2022-07-13       Impact factor: 3.752

3.  Association of monocyte tumor necrosis factor α expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease.

Authors:  Reena L Pande; Jonathan Brown; Stewart Buck; Whitney Redline; Jeanne Doyle; Jorge Plutzky; Mark A Creager
Journal:  J Vasc Surg       Date:  2014-08-02       Impact factor: 4.268

4.  Catecholamine-induced cardiac necroses: protective effect of leucocytopenia, influence of an S2 antagonist, thromboxanesynthetase inhibitor and prostacycline analogue.

Authors:  L Classen; G Michalsky; H Kammermeier
Journal:  Basic Res Cardiol       Date:  1993 Jan-Feb       Impact factor: 17.165

Review 5.  Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.

Authors:  J E Frampton; R N Brogden
Journal:  Drugs Aging       Date:  1995-12       Impact factor: 3.923

Review 6.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.